Cannasoul R&D Ltd.
Pioneer in cannabis research and analytics for pharmaceutical innovation.
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Cannasoul R&D Ltd. |
| Tagline | Pioneer in cannabis research and analytics for pharmaceutical innovation |
| Headquarters | Herzliya, Israel |
| Stage | Seed / Strategic |
| Business Model | B2B |
| Industry | Healthtech (cannabis therapeutics) |
| Technology Type | Biotech / Life Sciences |
| Geography | Middle East / North Africa |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout (Technion) |
| Funding Label | Undisclosed (one $4M strategic round confirmed) |
| Total Disclosed | $4M strategic from Synaptogenix [MarketScreener, Nov 2023] |
Links
PUBLIC
- Israeli Accreditation Authority listing (Cannasoul R&D Ltd. lab 473): https://www.israc.gov.il/?pg=lab&categoryid=246&articleid=271
- Neoteryx case profile (Cannasoul lab): https://www.neoteryx.com/canna-soul-laboratory
Executive Summary
PUBLIC
Cannasoul R&D Ltd. is a Herzliya-based cannabis research and analytics company that has just become the scientific anchor of one of the largest publicly traded cannabis platforms in Israel, giving it a credible path from academic chemistry to commercial therapeutics. The company was co-founded by Prof. Dedi Meiri, a cannabis researcher at the Technion - Israel Institute of Technology, together with the Technion Research & Development Foundation (TRDF), the university's commercialization arm [StreetInsider, Nov 2023]. Its core capability is a profiling platform that reportedly characterizes more than 100 cannabinoids and over 100 terpenes and flavonoids per strain, which the lab pairs with disease-specific research programs in oncology, epilepsy, and sleep disorders [Neoteryx]; [Benzinga, Nov 2023]. On the capital side, Synaptogenix acquired a roughly 25% minority stake for $4 million in late 2023 [MarketScreener, Nov 2023], and on November 3, 2025, InterCure Ltd. announced a strategic investment for an initial 28% ownership position with an option to increase to 51%, alongside a collaboration agreement and a Scientific Advisory Board to be chaired by Prof. Meiri [GlobeNewswire, Nov 2025]; [Investing.com, Nov 2025]. The business model is B2B research, licensing, and co-development, anchored to pharma-style endpoints rather than consumer cannabis branding. Over the next 12 to 18 months, the watch items are the closing mechanics of the InterCure transaction, any public disclosure of joint pipeline assets (particularly any IND-stage candidate emerging from the Synaptogenix psilocybin collaboration [PRNewswire]), and the trajectory of U.S. cannabis rescheduling, which several outlets cite as a near-term catalyst for international cannabis R&D platforms [Manila Times, Nov 2025].
Data Accuracy: GREEN -- Confirmed by GlobeNewswire, StreetInsider, MarketScreener, and Cannabis Business Times.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed / Strategic minority |
| Business Model | B2B research, licensing, co-development |
| Industry / Vertical | Healthtech, cannabis therapeutics |
| Technology Type | Biotech / Life Sciences (analytical chemistry, pharmacology) |
| Geography | Israel, with U.S. and global commercialization via partners |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout (Technion / TRDF) |
| Funding | Undisclosed total; $4M Synaptogenix strategic confirmed [MarketScreener, Nov 2023] |
Company Overview
PUBLIC
Cannasoul began life inside one of Israel's most prolific cannabis science programs and was structured from the start as a translational vehicle rather than a consumer brand. The company was co-founded by Prof. Dedi Meiri of the Technion - Israel Institute of Technology and the Technion Research & Development Foundation (TRDF), the university's technology transfer arm, which positions Cannasoul as a formal academic spinout with rights to research originating in Meiri's laboratory [StreetInsider, Nov 2023]. Prof. Meiri serves as Chairman and Chief Scientific Officer of the company [Markets Insider, Apr 2020]. The headquarters is in Herzliya, Israel, and the affiliated laboratory is listed in the Israeli Accreditation Authority's registry of accredited labs as Cannasoul R&D Ltd., lab number 473 [Israeli Accreditation Authority].
The milestone path is short but commercially meaningful. In April 2020, Cannasoul announced a joint program with terpene formulation specialist Eybna to test a proprietary terpene blend designed to modulate the cytokine storm associated with severe viral infection, an early signal that the company intended to operate at the pharmacology rather than wellness end of the cannabis spectrum [Markets Insider, Apr 2020]. In November 2023, Synaptogenix, a Nasdaq-listed neurotherapeutics company, acquired a roughly 25% minority stake in Cannasoul for $4 million, and the two companies announced a research and development partnership extending to psilocybin-based therapeutics in addition to cannabis [StreetInsider, Nov 2023]; [MarketScreener, Nov 2023]; [PRNewswire]. The most recent milestone, on November 3, 2025, is the strategic investment and collaboration with InterCure Ltd., under which InterCure takes an initial 28% ownership position with an option to move to 51% and Prof. Meiri is expected to chair a newly formed Scientific Advisory Board at InterCure [GlobeNewswire, Nov 2025]; [Investing.com, Nov 2025].
Data Accuracy: GREEN -- Confirmed by GlobeNewswire, StreetInsider, MarketScreener, and the Israeli Accreditation Authority registry.
Product and Technology
MIXED
Cannasoul's product is best understood as a research-grade analytical and pharmacology platform that feeds a co-development pipeline, rather than a packaged SKU sold to end users. According to a profile published by Neoteryx, Cannasoul's proprietary profiling methods enable analysis of over 100 cannabinoids and over 100 terpenes and flavonoids per cannabis strain, which the company describes as the broadest available coverage in the category [Neoteryx]. That depth of chemotype characterization is what allows the lab to map specific botanical fingerprints to disease-relevant biological activity, the chemistry-to-pharmacology bridge that distinguishes a research platform from a testing lab. The lab itself is formally accredited and listed in the Israeli national lab registry, which is a meaningful regulatory credential for any partner intending to use Cannasoul data in a regulated submission [Israeli Accreditation Authority].
The research program runs across several disease areas. Benzinga reported that Cannasoul has developed technology aimed at large disease markets including leukemia, epilepsy, and sleep disorders [Benzinga, Nov 2023]. The Eybna collaboration targeted viral infection via cytokine storm modulation [Markets Insider, Apr 2020], and a Professionally Cannabis podcast appearance referenced research streams in breast cancer and sleep disorders [Professionally Cannabis Podcast]. The Synaptogenix tie-up expanded the platform's scope beyond cannabinoids to include psilocybin therapeutics, indicating that the underlying screening and pharmacology methods are intended to be applicable to a broader class of botanically derived molecules [PRNewswire]; [Benzinga, Nov 2023].
What the public record does not yet contain is a disclosed clinical-stage asset with a named indication, dosing form, and trial registry entry. Investors evaluating the platform should treat the disease-area mentions as research programs rather than as IND-stage candidates until a sponsor (most likely InterCure or Synaptogenix going forward) discloses one. The InterCure announcement frames the collaboration as covering "research, development and commercialization of evidence-based cannabis therapeutics," which is the right language but is not yet attached to a specific molecule on a public timeline [StockTitan, Nov 2025].
Data Accuracy: GREEN -- Confirmed by Neoteryx, Benzinga, Markets Insider, and the Israeli Accreditation Authority.
Market Research and Opportunity
PUBLIC
The market context for Cannasoul has shifted in 2025 from a slow regulatory grind into a credible inflection scenario, and the company sits on the research side of that shift rather than the retail side. Multiple outlets reporting on the InterCure transaction explicitly tied the strategic logic to the Trump administration reportedly exploring rescheduling cannabis from Schedule I to Schedule III in the United States, a move that several cited press releases describe as potentially opening international cannabis companies to a much larger addressable U.S. market [Manila Times, Nov 2025]; [Yahoo Finance, Nov 2025]; [QuiverQuant, Nov 2025]. Rescheduling, if it happens, would not directly turn cannabis into a conventional pharmaceutical, but it would lower research friction and open Section 280E tax relief for U.S. operators, both of which raise the value of a research platform that can supply pharma-grade data and IP.
No named third-party TAM, SAM, or SOM figure for the cannabis therapeutics or cannabis analytics segments appears in the captured sources, so a sized chart of the segment is not appropriate here. What the sources do support is a directional view of where Cannasoul's research programs intersect with sizeable disease markets. The disease areas named in Cannasoul's research portfolio (oncology including leukemia and breast cancer, epilepsy, sleep disorders, and viral infection via cytokine modulation) are each pharmaceutical categories with established blockbuster precedents, and a single licensable molecule or formulation in any of them could carry value far above the company's current capitalization [Benzinga, Nov 2023]; [Markets Insider, Apr 2020]; [Professionally Cannabis Podcast].
| Demand driver | Evidence | Source |
|---|---|---|
| Potential U.S. cannabis rescheduling to Schedule III | Cited as the regulatory backdrop motivating the InterCure transaction | [Manila Times, Nov 2025] |
| Pharma interest in psychedelic and botanical therapeutics | Synaptogenix expanded its R&D scope to include psilocybin via Cannasoul | [PRNewswire]; [Benzinga, Nov 2023] |
| Demand for chemotype-level cannabis characterization | Cannasoul's profiling covers 100+ cannabinoids and 100+ terpenes and flavonoids per strain | [Neoteryx] |
| Strategic capital flowing to Israeli cannabis R&D | InterCure took an initial 28% stake with an option to 51% in Nov 2025 | [GlobeNewswire, Nov 2025] |
The table is a directional read of demand drivers rather than a sized market, and the most important row is the rescheduling row because it is the variable that most plausibly re-rates the entire category in the next 12 to 18 months. Adjacent and substitute markets worth tracking include traditional botanical drug discovery, psychedelic therapeutics (where Synaptogenix is already the partner), and contract research organizations serving the licensed-producer ecosystem, all of which compete for the same pharma R&D budgets.
Data Accuracy: YELLOW -- Demand drivers corroborated by multiple outlets; no named TAM/SAM/SOM figure was disclosed in the captured sources.
Competitive Landscape
MIXED
Cannasoul occupies an unusual position because it competes less with consumer cannabis brands and more with academic labs, contract research organizations, and the internal R&D arms of cannabis pharma companies.
The competitive map breaks roughly into three layers. First, academic and institutional cannabis research groups (the Hebrew University Multidisciplinary Center on Cannabinoid Research and various U.S. and Canadian university programs) compete for talent, grant funding, and publication priority. Cannasoul's structural advantage against this layer is that it is a commercial entity with a TRDF spinout vehicle behind it, which means discoveries can be packaged into licensable IP rather than left to drift through academic technology transfer queues [StreetInsider, Nov 2023]. Second, contract analytical labs serving the cannabis industry compete for routine potency, pesticide, and terpene testing volume; Cannasoul's defense here is its claim of profiling more than 100 cannabinoids and 100 terpenes and flavonoids per strain, a depth that pushes the lab into pharmaceutical-grade characterization rather than commodity QA work [Neoteryx]. Third, vertically integrated cannabis pharma companies (companies with internal medical-cannabis R&D such as the established European medical-cannabis producers) operate their own pipelines; Cannasoul's response to that layer has been to align with two such platforms, Synaptogenix on the psychedelic and neuroscience side and InterCure on the cannabis commercialization side, rather than try to build a competing commercial footprint [PRNewswire]; [GlobeNewswire, Nov 2025].
The most defensible edge today is the combination of Prof. Meiri's research reputation, the accredited Herzliya lab, and the breadth of the chemotype profiling library, because that combination is hard to replicate without years of method development and a publication track record. The most perishable element is exclusivity: the InterCure deal is structured as a strategic minority with an option to majority, and the Synaptogenix stake predates it, which means Cannasoul's research output will be channeled through partner-driven commercialization decisions rather than its own go-to-market [Investing.com, Nov 2025]; [MarketScreener, Nov 2023]. The most likely exposure is on the commercial side: Cannasoul does not own distribution into U.S. dispensaries, does not run its own clinical trials at scale, and does not yet have a publicly disclosed IND-stage candidate, so a competitor that already owns one of those three (a U.S.-listed cannabis pharma with a Phase 2 asset, for example) could outrun the platform on time-to-market for any given indication.
The most plausible 18-month competitive scenario has two named outcomes. Winner if U.S. rescheduling proceeds and InterCure exercises its option to 51%: Cannasoul becomes the de facto research engine of a scaled, internationally listed cannabis pharma platform, with a clear path to publishing IND-enabling data on at least one named candidate. Loser if rescheduling stalls and partner balance sheets tighten: the platform retains its scientific reputation but its commercialization timeline elongates, and the value of the Synaptogenix and InterCure stakes compresses with the broader cannabis sector multiple.
Data Accuracy: YELLOW -- Partner relationships confirmed by GlobeNewswire and StreetInsider; no head-to-head competitor was named in the captured sources, so the segment map is analyst-constructed.
Opportunity
PUBLIC
If Cannasoul executes, the prize is to be the scientific layer that the next generation of regulated cannabis and botanical therapeutics is built on, in much the way specialized chemistry platforms have anchored other emerging pharma categories.
The headline opportunity. The single largest plausible outcome is for Cannasoul to become the default cannabis pharmacology platform for at least one publicly traded operator (InterCure today, potentially others tomorrow) and to convert that position into a portfolio of licensed or co-owned therapeutic assets across oncology, neurology, and sleep. The cited evidence makes this reachable rather than aspirational: the lab is already accredited [Israeli Accreditation Authority], the chemotype library is already the broadest publicly described in the category [Neoteryx], a Nasdaq-listed neurotherapeutics company has already paid $4 million for a roughly 25% stake [MarketScreener, Nov 2023], and a leading Israeli cannabis operator has now committed to an initial 28% with a path to 51% along with a collaboration agreement and a board-level Scientific Advisory Board chair for the founder [GlobeNewswire, Nov 2025]. Two strategic acquirers paying real money for governance rights is a strong external validation that the platform is more than a single-PI research lab.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Embedded R&D engine for a global cannabis pharma | InterCure exercises its option to 51% and Cannasoul becomes the captive research platform feeding a multi-indication pipeline | InterCure option exercise plus first IND-enabling data package | InterCure has already negotiated the option and structured a collaboration agreement [GlobeNewswire, Nov 2025] |
| Multi-modality botanical platform | Cannasoul extends its profiling and pharmacology methods beyond cannabinoids into psilocybin and other botanicals via Synaptogenix and additional partners | A second psychedelic or botanical partnership announced alongside Synaptogenix | The Synaptogenix relationship already explicitly includes psilocybin R&D [PRNewswire]; [Benzinga, Nov 2023] |
| Regulatory tailwind re-rating | U.S. rescheduling to Schedule III opens a much larger addressable market for international cannabis R&D platforms, lifting the value of every Cannasoul partnership | DEA / administration action on rescheduling | Cited press coverage frames rescheduling as a near-term catalyst already shaping deal logic [Manila Times, Nov 2025]; [Yahoo Finance, Nov 2025] |
What compounding looks like. The flywheel is data-driven. Every strain Cannasoul profiles adds rows to a chemotype-to-bioactivity database that is, by the company's own description, already the broadest publicly characterized in cannabis [Neoteryx]. Each new partner program (Eybna on terpenes, Synaptogenix on psilocybin, InterCure on cannabis therapeutics) feeds that database with new biological assays and disease endpoints, which in turn raises the probability that the next screen produces a licensable hit. Because the underlying methods are method-based rather than indication-specific, a win in one disease area (sleep, for example) does not exhaust the platform; it makes the next indication faster and cheaper to screen. Distribution lock-in compounds on top of this through equity: with Synaptogenix and InterCure both holding meaningful stakes, the platform is structurally embedded in two listed pharma vehicles that have their own incentive to fund and disclose its progress [MarketScreener, Nov 2023]; [Investing.com, Nov 2025].
The size of the win. No named third-party valuation comparable for a cannabis research platform appears in the captured sources, so any number here is a scenario rather than a forecast. Directionally, if Cannasoul becomes the captive R&D engine for a scaled international cannabis pharma and contributes one approved or late-stage asset in a major indication such as epilepsy or oncology (scenario, not a forecast), the value of its equity position to its strategic holders would be measured in multiples of the disclosed $4 million Synaptogenix entry price [MarketScreener, Nov 2023]. The more conservative win, also worth naming, is that Cannasoul simply becomes the standard analytical reference lab for partner pipelines and accredited regulated submissions, which is a smaller but more certain outcome and one that the existing accreditation, partnerships, and chemotype library already point toward [Israeli Accreditation Authority]; [GlobeNewswire, Nov 2025].
Data Accuracy: GREEN -- Scenarios are built on partnership, stake, and accreditation facts confirmed by GlobeNewswire, MarketScreener, StreetInsider, Neoteryx, and the Israeli Accreditation Authority.
Sources
PUBLIC
[Cannabis Business Times, Nov 2025] InterCure, Cannasoul Partner to Advance Cannabis Science, Pharmaceutical Innovation | https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cannabis-industry-research/news/15770819/intercure-cannasoul-partner-to-advance-cannabis-science-pharmaceutical-innovation
[StockTitan, Nov 2025] INCR Stock Price, News & Analysis - Intercure | https://www.stocktitan.net/overview/INCR/
[GlobeNewswire, Nov 2025] InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation | https://www.globenewswire.com/news-release/2025/11/03/3179258/0/en/InterCure-and-Cannasoul-Sign-Strategic-Investment-and-Collaboration-Agreements-to-Advance-Cannabis-Science-and-Pharmaceutical-Innovation.html
[The Manila Times, Nov 2025] InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation | https://www.manilatimes.net/2025/11/03/tmt-newswire/globenewswire/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation/2214425
[Yahoo Finance, Nov 2025] InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation | https://finance.yahoo.com/news/intercure-cannasoul-sign-strategic-investment-133000283.html
[Markets Insider, Apr 2020] Eybna and CannaSoul, Top Cannabis R&D Firms, Join Forces to Prove a Proprietary Terpene Formulation for Treating Viral Infections via Modulation of Cytokine Storm | https://markets.businessinsider.com/news/stocks/eybna-and-cannasoul-top-cannabis-r-d-firms-join-forces-to-prove-a-proprietary-terpene-formulation-for-treating-viral-infections-via-modulation-of-cytokine-storm-1029119056
[Professionally Cannabis Podcast] Dr. David (Dedi) Meiri, Technion - Israel Institute of Technology & CannaSoul | https://contenthub.gcintelligence.com/professionally-cannabis-podcast-dr-david-dedi-meiri-technion-israel-institute-of-technology-cannasoul/
[QuiverQuant, Nov 2025] InterCure Enters Research Partnership with Cannasoul to Innovate Cannabis Therapeutics Amid Regulatory Changes in the U.S. | https://www.quiverquant.com/news/InterCure+Enters+Research+Partnership+with+Cannasoul+to+Innovate+Cannabis+Therapeutics+Amid+Regulatory+Changes+in+the+U.S.
[Investing.com, Nov 2025] InterCure acquires 28% stake in cannabis research firm Cannasoul | https://www.investing.com/news/company-news/intercure-acquires-28-stake-in-cannasoul-research-firm-cannasoul-93CH-4327282
[StreetInsider, Nov 2023] Synaptogenix Acquires Significant Stake in Cannasoul Analytics Ltd. Co-founded by The Technion - Israel Institute of Technology | https://www.streetinsider.com/PRNewswire/Synaptogenix+Acquires+Significant+Stake+in+Cannasoul+Analtyics+Ltd.+Co-founded+by+The+Technion+-+Israel+Institute+of+Technology/22351489.html
[Benzinga, Nov 2023] Synaptogenix And Cannasoul Partner To Support Research And Development Of Pharmaceutical Therapeutics | https://www.benzinga.com/general/biotech/23/11/35565604/cutting-edge-cannabis-products-on-the-horizon-as-biotech-co-funds-new-research
[PitchBook, 2025] Cannasoul Analytics Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/491282-74
[Neoteryx] Cannabis R&D in Pre-Clinical, Clinical Trials, Pharmacokinetic | https://www.neoteryx.com/canna-soul-laboratory
[MarketScreener, Nov 2023] Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million | https://www.marketscreener.com/quote/stock/SYNAPTOGENIX-INC-120797989/news/Synaptogenix-Inc-acquired-25-minority-stake-in-Cannasoul-Analytics-Ltd-for-4-million-45246805/
[Israeli Accreditation Authority] Cannasoul R&D Ltd. lab 473 listing | https://www.israc.gov.il/?pg=lab&categoryid=246&articleid=271
Articles about Cannasoul R&D Ltd.
- Cannasoul Is Putting Israeli Cannabis Pharmacology on InterCure's Balance Sheet — The Technion spinout led by Prof. Dedi Meiri now has a strategic backer with up to 51% ownership and a path toward clinical-grade cannabinoid therapeutics.